{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:29:21Z","timestamp":1747171761251,"version":"3.40.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["trasci.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.transci.2021.103293","type":"journal-article","created":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T03:11:52Z","timestamp":1634353912000},"page":"103293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SARS-Coronavirus-2 seroprevalence in asymptomatic healthy blood donors: Indicator of community spread"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5172-0193","authenticated-orcid":false,"given":"Pratibha","family":"Kale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niharika","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekta","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meenu","family":"Bajpai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2020","series-title":"WHO Director-General\u2019s opening remarks at the media briefing on COVID-19\u201411 March 2020","author":"World Health Organization","key":"10.1016\/j.transci.2021.103293_bib0005"},{"key":"10.1016\/j.transci.2021.103293_bib0010","unstructured":"Government of India. COVID-19 dashboard. May 13, 2021. https:\/\/www.mygov.in\/covid-19 (Accessed 13 May 2021)."},{"key":"10.1016\/j.transci.2021.103293_bib0015","unstructured":"Second interim National Guidance to blood transfusion services in India in light of COVID-19 pandemic, 25th June 2020. https:\/\/www.mohfw.gov.in\/pdf\/2ndNBTCGuidanceinLightofCOVID19Pandemic.pdf [Accessed 13 May 2021]."},{"key":"10.1016\/j.transci.2021.103293_bib0020","article-title":"Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19","volume":"6044","author":"Li","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.transci.2021.103293_bib0025","unstructured":"Delhi Government Health bulletin. https:\/\/delhifightscorona.in\/wp-content\/themes\/gocoronago\/health-bulletin-pdfs\/09-23.pdf [Accessed 13 May 2021]."},{"key":"10.1016\/j.transci.2021.103293_bib0030","article-title":"The seroprevalence and trends of SARS-CoV-2 in Delhi, India: a repeated population-based seroepidemiological study","author":"Sharma","year":"2021","journal-title":"Transactions of The Royal Society of Tropical Medicine and Hygiene"},{"issue":"October (5)","key":"10.1016\/j.transci.2021.103293_bib0035","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.transci.2018.08.005","article-title":"Pattern of distribution of 35 red cell antigens in regular voluntary blood donors of South Gujarat, India","volume":"57","author":"Shah","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2021.103293_bib0040","unstructured":"Government of India. COVID-19 dashboard. September 30, 2020. https:\/\/www.mygov.in\/covid-19\/ [Accessed 30 September 2020]."},{"issue":"6524","key":"10.1016\/j.transci.2021.103293_bib0045","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1126\/science.abe1916","article-title":"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors","volume":"371","author":"Uyoga","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.transci.2021.103293_bib0050","article-title":"The effect of strict lock down measures on Covid-19 seroprevalence rate and herd immunity","author":"Sughayer","year":"2020","journal-title":"MedRxiv Preprint"},{"issue":"1","key":"10.1016\/j.transci.2021.103293_bib0055","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1038\/s41467-020-18468-8","article-title":"SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area","volume":"11","author":"Ng","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.transci.2021.103293_bib0060","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.28.2001285","article-title":"SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020","volume":"25","author":"Fischer","year":"2020","journal-title":"Eurosurveillance"},{"issue":"2","key":"10.1016\/j.transci.2021.103293_bib0065","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/cid\/ciaa849","article-title":"Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors","volume":"72","author":"Erikstrup","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"November (1)","key":"10.1016\/j.transci.2021.103293_bib0070","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1038\/s41467-020-19481-7","article-title":"Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands","volume":"11","author":"Slot","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.transci.2021.103293_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104880","article-title":"Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors","volume":"181","author":"Gallian","year":"2020","journal-title":"Antivir Res"},{"issue":"15","key":"10.1016\/j.transci.2021.103293_bib0080","article-title":"Cluster of COVID- 19 in Northern France: a retrospective closed cohort study","volume":"26","author":"Fontanet","year":"2021","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.transci.2021.103293_bib0085","article-title":"Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020","volume":"25","author":"Thompson","year":"2020","journal-title":"Euro-surveillance"},{"key":"10.1016\/j.transci.2021.103293_bib0090","article-title":"Seroprevalence of IgG and IgM anti-SARS-CoV-2 among voluntary blood donors in Rio de Janeiro","author":"Luiz Amorim","year":"2020","journal-title":"Brazil. MedRxiv"},{"issue":"3","key":"10.1016\/j.transci.2021.103293_bib0095","first-page":"181","article-title":"SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak","volume":"19","author":"Valenti","year":"2021","journal-title":"Blood Transfus."},{"key":"10.1016\/j.transci.2021.103293_bib0100","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.24.2001031","article-title":"Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020","volume":"25","author":"Percivalle","year":"2020","journal-title":"Eurosurveillance"},{"issue":"3","key":"10.1016\/j.transci.2021.103293_bib0105","doi-asserted-by":"crossref","first-page":"103118","DOI":"10.1016\/j.transci.2021.103118","article-title":"Seroprevalence of SARS-Coronavirus 2 among asymptomatic healthy blood donors from healthcare and non-healthcare settings: Implications for safety of blood donors and blood collection staff during blood donation","volume":"60","author":"Pandey","year":"2021","journal-title":"Transfus Apher Sci"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050221002937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050221002937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T16:24:54Z","timestamp":1741623894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050221002937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1473050221002937"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2021.103293","relation":{},"ISSN":["1473-0502"],"issn-type":[{"type":"print","value":"1473-0502"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-Coronavirus-2 seroprevalence in asymptomatic healthy blood donors: Indicator of community spread","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2021.103293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103293"}}